Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.
Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.
Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.
Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.
For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Horizon Therapeutics and the Cubs have partnered for a Legacy Partnership, launching a Cubs STEAM Program aimed at engaging middle and high school students in science through baseball. The program will feature a citywide science camp and fair, facilitating hands-on learning about the intersection of science and baseball. Additionally, the partnership includes an event during Spring Training 2022 to raise awareness about rare diseases. Horizon's initiative seeks to nurture future science leaders while highlighting the challenges faced by those with rare diseases.
Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first patient in the FORWARD trial, assessing a new monthly dosing of 16 mg KRYSTEXXA with methotrexate for treating uncontrolled gout. This trial aims to lower treatment frequency, potentially enhancing patient experience. The primary endpoint measures responder rates in maintaining low serum uric acid levels. With 30 participants targeted, the protocol remains unapproved by health authorities. Safety concerns exist regarding anaphylaxis and infusion reactions during treatment.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that Mitsubishi Tanabe Pharma Corporation received approval for UPLIZNA from the Japanese Ministry of Health. This drug is aimed at preventing relapses in neuromyelitis optica spectrum disorder (NMOSD). MHPC holds rights for UPLIZNA's development in several Asian markets. Horizon stands to gain milestone payments and sales-related revenues. Tim Walbert emphasized the approval's significance for NMOSD patients and Horizon's commitment to expanding treatment options globally.
Horizon Therapeutics plc (Nasdaq: HZNP) has launched The Horizon Prize, an annual global innovation challenge in partnership with MIT Solve, aimed at enhancing diagnosis and care for individuals with rare diseases. Each year, the challenge will focus on a unique question to stimulate innovative solutions. This year’s inquiry targets utilizing technology to expedite accurate care for rare disease patients. With an annual funding pool of up to $150,000 for two teams, the initiative seeks solutions leveraging big data, patient advocacy, and collaboration among stakeholders in the healthcare ecosystem.
Horizon Therapeutics (Nasdaq: HZNP) has acquired Viela Bio (Nasdaq: VIE) for $53.00 per share, a transaction valued at over $3 billion. This acquisition enhances Horizon's commercial portfolio in rare diseases, particularly with UPLIZNA, the first FDA-approved treatment for neuromyelitis optica spectrum disorder. The deal will strengthen Horizon's R&D capabilities and add a mid-stage biologics pipeline targeting autoimmune diseases. However, Horizon expects a $140 million decrease in adjusted EBITDA for 2021 due to increased R&D expenditures.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Cowen and Company 41st Annual Health Care Conference (Virtual) on March 2, 2021, at 1:30 p.m. ET. The event will be webcast live, and the link can be found on Horizon's website. A replay of the presentation will be available afterward. Horizon focuses on developing therapeutics for patients with rare and rheumatic diseases, aiming to transform lives through science and compassion.
Horizon Therapeutics plc (Nasdaq: HZNP) reported record financial results for Q4 and the full year 2020, highlighting a 105% increase in Q4 net sales to $745.3 million and 69% growth in FY 2020 to $2.2 billion. The company announced positive guidance for 2021, projecting net sales between $2.70 billion to $2.80 billion. CEO Tim Walbert emphasized the successful launch of TEPEZZA and a definitive agreement to acquire Viela Bio, adding to its robust pipeline. However, net income saw a significant decline of 68% in Q4.
FAQ
What is Horizon Therapeutics?
What products does Horizon Therapeutics offer?
What recent achievements has Horizon Therapeutics made?
Who is acquiring Horizon Therapeutics?
How is Horizon Therapeutics contributing to medical science?
What is the mission of Horizon Therapeutics?
How can I learn more about Horizon Therapeutics?
What is the significance of Horizon’s recent agreement with the FTC?
Where is Horizon Therapeutics headquartered?
What is the focus of Horizon's research and development efforts?
